

Swiss Tropical and Public Health Institute Schweizerisches Tropen- und Public Health-Institut Institut Tropical et de Santé Publique Suisse

Associated Institute of the University of Basel

### **Department of Epidemiology & Public Health**

# An economic and health system perspective to global health challenges

**Fabrizio Tediosi**, Department of Epidemiology and Public Health, Swiss TPH - fabrizio.tediosi@swisstph.ch - twitter @fabrizio2570

### **1.** Growing economic relevance of health (sector)

### **Total health expenditure:**


- 10% of global GDP in 2014
- US\$Int 1272 per capita per year in 2014
- Huge variations across countries: US\$Int 93 LICs- 4609 HICs in 2014

Income is the main determinant of health expenditure growth









Total expenditure on health

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for World Health Organization which there may not yet be full agreement.

Data Source: Global Health Observatory, WHO Map Production: Information Evidence and Research (IER)














Per capita total expenditure on health

at average exchange rate (US\$), 2014 \*



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for World Health Organization which there may not yet be full agreement.

Data Source: Global Health Observatory, WHO Map Production: Information Evidence and Research (IER)













# **1.** Growing economic relevance of health (sector)

Health sector both labor and brain intensive

Investments in health sector have impact on quantity and quality of employment











The world's largest employers:

- 1. US Department of Defense 3.2 million
- 2. People's Liberation Army (China) 2.3 million
- 3. Walmart 2.1 million
- 4. McDonald's 1.9 million
- 5. UK NHS 1.7 million
- 6. China National Petroleum Corporation 1.6 million
- 7. State Grid Corporation of China 1.5 million
- 8. Indian Railways 1.4 million
- 9. Indian Armed Forces 1.3 million
- 10. Hon Hai Precision Industry (Foxconn) 1.2 million ends





### **1.** Growing economic relevance of health (sector)


Commercial/Business practices & interests have significant impact on health and health care delivery – e.g.

- (Big) Tobacco
- (Big) Food
- (Big) Pharma

Importance of global, national, and local regulation and governance







### **1.** Growing economic relevance of health (sector)

Commercial/Business practices & interests have significant impact on health and health care delivery

### **Global Health Governance challenges-**

- e.g. WHO Funding sources (budget 2014-15):
- Assessed contributions: 23.4% (929 M US\$)
- Voluntary contributions: 76.6% (3049 M US\$)







**2.** Paradigm shift: health from consequence to determinant of economic development

Traditional economic thinking: income growth is a key factor for improved population health

• Policies prescribed by international financial institutions for LICs focused on growth in GDP to the neglect and even the detriment of population health

Health more relevant in global development policies








**2.** Paradigm shift: health from consequence to determinant of economic development

Strong empirical evidence that relation health and development is bi-directional • WHO Commission on Macroeconomics and health (2000)

Health more relevant in global development policies

Growth in global health financing





Paradigm shift: health from consequence to determinant 2. of economic development

The Lancet Commissions





### Global health 2035: a world converging within a generation

Dean T Jamison\*, Lawrence H Summers\*, George Alleyne, Kenneth J Arrow, Seth Berkley, Agnes Binagwaho, Flavia Bustreo, David Evans, Richard G A Feachem, Julio Frenk, Gargee Ghosh, Sue J Goldie, Yan Guo, Sanjeev Gupta, Richard Horton, Margaret E Kruk, Adel Mahmoud, Linah K Mohohlo, Mthuli Ncube, Ariel Pablos-Mendez, K Srinath Reddy, Helen Saxenian, Agnes Soucat, Karen H Ulltveit-Moe, Gavin Yamey

http://www.cddep.org/projects/lancet\_commission\_investing\_health







### **Millennium Development Goals**

In 2000 Millennium Development Goals for 2015








### Paradigm shift: health from consequence to determinant 2. of economic development

Unprecedented funding to global health – now over?

http://vizhub.healthdata.org/fgh/

From: Sources and Focus of Health Development Assistance, 1990-2014 JAMA. 2015;313(23):2359-2368. doi:10.1001/jama.2015.5825 DAH by channel, 1990-2014





🛑 Regional development banks
🛑 World Bank – IBRD
🛑 World Bank – IDA
International NGOs
US NGOs
Other foundations
BMGF
Global Fund
Gavi
European Commission
UNICEF, UNFPA, UNAIDS, PAHO
🔵 WHO
BILATERAL AGENCIES
Other
Australia
🛑 Canada
France
Germany
🛑 ик
US
*2013 and 2014 are
preliminary estimates.

### **Health in Sustainable Development Goals**









### Health in Sustainable Development Goals





### **SDG 3:** ENSURE HEALTHY LIVES AND PROMOTE WELL-BEING FOR ALL AT ALL AGES

**TARGET 3.8: ACHIEVE UNIVERSAL HEALTH COVERAGE, INCLUDING FINANCIAL RISK PROTECTION,** ACCESS TO QUALITY ESSENTIAL HEALTH-CARE SERVICES, MEDICINES AND VACCINES FOR ALL

### MDG UNFINISHED AND EXPANDED AGENDA

3.1: Reduce maternal mortality

**3.2:** End preventable newborn and child deaths

3.3: End the epidemics of AIDS, TB, malaria and NTDs

and combat hepatitis, waterborne and other communicable diseases

3.7: Ensure universal access to sexual and reproductive healthcare services

### **NEW SDG 3 TARGETS**

3.4: Reduce mortality from NCDs and promote mental health

3.5: Strengthen prevention and treatment of substance abuse

3.6: Halve global deaths and injuries from road traffic accidents

3.9: Reduce deaths and illnesses from hazardous chemicals and air, water and soil pollution and contamination

### SDG 3 MEANS OF IMPLEMENTATION TARGETS

3.a: Strengthen implementation of framework convention on tobacco control

3.b: Provide access to medicines and vaccines for all, support R&D of vaccines and medicines for all

3.c: Increase health financing and health workforce in developing countries

3.d: Strengthen capacity for early warning, risk reduction and management of health risks

INTERACTIONS WITH ECONOMIC, OTHER SOCIAL AND ENVIRONMENTAL SDGs AND SDG 17 ON MEANS OF IMPLEMENTATION







## **3.** Relevance of social determinants of health

The greatest share of health problems is attributable to the **social conditions in** which people live and work that are key determinants of health

Health inequalities are caused by inequitable distribution of more fundamental social, political and economic forces







### 3. Relevance of social determinants of health

Health depends on many factors and policies that are outside of the remit of health ministries

Action needed

- to improve basic living conditions -health services, education, and working conditions;
- to reduce inequalities in power and resources;
- to create transparency by monitoring and measuring inequalities in health.





## 4. Inequalities - equity in health and access to care

Despite dramatic improvements in average population health, disparities between the poorest and least poor have been increasing:


- in economic burden of ill health;
- in access to health care; and
- in health outcomes

Health systems are ill equipped to identify and respond to health inequities, and often cause greater inequity





### 4. Inequalities in health



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization Map Production: Health Statistics and Information Systems (HSI) World Health Organization


© WHO 2015. All rights reserved.

Organization





### 4. Inequalities in health



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, cityor area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization Map Production: Information Evidence and Research (IER) World Health Organization







## 4. Inequalities in health and access to care

**Examples**:

Maternal mortality:

- http://apps.who.int/gho/data/node.sdg.3-1-viz?lang=en

NCDs - Mortality rate attributed to cardiovascular disease (CVD), cancer, diabetes or chronic respiratory disease (CRD) - http://apps.who.int/gho/data/node.sdg.3-4-viz-1?lang=en

### **UHC indicators**:

- http://apps.who.int/gho/cabinet/uhc.jsp









### 4. Inequalities in access to care

### Inequality in reproductive, maternal, newborn and child health (RMNCH) interventions

Composite coverage index: weighted score reflecting cover age of eight reproductive, maternal, newborn and child health interventions along the continuum of care











### 4. Inequalities in health and access to care

Wealthy groups often benefit more than the poor from government spending

**Private sector weakly governed/regulated** - the poorest often receive the poorest quality of care within the private sector







### A health system perspective

 Health outcomes mediated by complex interactions between diseases, environment, and socio-economic systems at micro and macro levels

– The "black box misconception": "we must simply get technologies and other inputs in place and then outputs will somehow walk their way" (Frank J., PLoS Med, 2010)



### A health system perspective

### **Characteristics of a sustainable Health System**

### Affordable

- Public health
- High value interventions
- Low OOPs

### Acceptable

- Stakeholders involvement
- Patient Involvement
- Trust

### Adaptable

• Respond to changes in BoD, Social & cultural, Tech etc.





# Health system complexity

### A framework of connected sub-systems



"A system is not the sum of its parts; It is the product of the interaction of its parts"

What happens between the sub-systems is more important than what goes on within them; and is usually neglected".

Source: de Savigny and Adam (2009)






## Health system complexity

Medicines & Technologies sub-system – Tanzania 2007

Health systems are complex adaptive systems

All building blocks are fragmented







### A health system (and economic) perspective

Three sets of health challenges:

- 1. The huge health challenges still suffered by vulnerable groups in low and middle income countries
- 2. The shift in the disease burden towards non communicable diseases
- 3. The burden of medical expenditure on households and societies





### Challenge 1: The huge health challenges of vulnerable groups in low and middle income countries




Figure 5: YLL and YLD cause composition of DALY rates by sociodemographic status vigintile

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Aug 27.





## **Challenge 1: The huge health challenges of vulnerable** groups in low and middle income countries


Most of the BoD suffered by vulnerable groups is for communicable diseases, neonatal, maternal, nutritional conditions – that can be prevented or treated with "available" interventions relatively inexpensive

Scaling up Effective Coverage of available preventive and curative interventions would dramatically reduce this burden



### Example: Effective coverage of malaria case management

A few studies estimated low effective coverage of malaria case management in malaria endemic areas in Africa (e.g. INESS http://indepthnetwork.org/projects/iness)



### System effectiveness of artemether-lumefantrine in Tanzania

Source: INESS http://indepth-network.org/projects/iness






## **Example: Effective coverage of malaria case management**

We used Demographic Health Surveys and published sources to estimated effective coverage of Malaria Case Management in 43 high burden African Countries

Effective Coverage (E) and Access to Any Provider (A) by Country (%).




Galactionova K, Tediosi F, et al (2015) Effective Coverage and Systems Effectiveness for Malaria Case Management in Sub-Saharan African Countries. PLoS 10(5): e0127818. doi:10.1371/


Effective coverage and malaria service indicators








### Effective coverage (E) and Access to malaria treatments (A)



Galactionova K, Tediosi F, de Savigny D, Smith T, Tanner M (2015). Effective Coverage and Systems Effectiveness for Malaria Case Management in Sub-Saharan African Countries. PLoS ONE 10(5): e0127818. doi:10.1371/journal.pone.0127818



### Effective coverage of malaria case management: Nigeria






# Swiss TPH

### Access to treatment

### Access to formal care

# Bottlenecks in service provision: each country has different challenges Swiss TPH




Galactionova K, Tediosi F et al. PLoS ONE 10(5): e0127818. doi:10.1371/journal.pone.0127818

### **Example: Impact of strategies to control and eliminate Neglected Tropical Diseases**

- Neglected Tropical Diseases affect vulnerable people mainly in marginalized areas of low and middle income countries
- Many of them could be prevented or treated with relatively simple interventions e.g. preventive chemotherapy

Figure 2.13. Number of people (millions) requiring preventive chemotherapy for selected neglected tropical diseases with intervention coverage and number of countries requiring preventive chemotherapy



WHO-WB Tracking universal health coverage: first global monitoring report http://www.who.int/healthinfo/universal\_health\_coverage/report/2015/en





# **Example: Impacts of strategies to control and eliminate Neglected Tropical Diseases**

### Lymphatic Filariasis

- Chronic forms of morbidity: hydrocele and lymphoedema
- Global program to eliminate LF with Mass Drug Adminisstration (MDA) of DEC + albendazole or ivermectin+ albendazole covering at least 65% of the at-risk population for at least 5 years
- A key challenge for the elimination of LF is the expansion of geographic coverage of MDA programmes
- Prior studies have not considered long terms health benefits, costs, and cost-effectiveness associated with scaling-up geographic coverage






# **Example: Impacts of strategies to control and eliminate Neglected Tropical Diseases**

### **Lymphatic Filariasis**

LF prevalent in poor populations in several countries (2.77 million DALYs)



Distribution of lymphatic filariasis and status of preventive chemotherapy (PC) in endemic countries, 2016

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not vet be full agreement. © WHO 2017. All rights reserved

Data Source: World Health Organization Map Production: Control of Neglected Tropical Diseases (NTD) World Health Organization







# Scenarios compared for elimination and eradication of **Lymphatic Filariasis**

Key features of the proposed scenarios for elimination and eradication of LF

	Elimination (comparator)	Eradication I	Eradication II	Eradication III
Intervention	MDA	MDA	MDA	MDA
Coverage rate	85%	85%	85%	85%
Countries considered	All LF endemic countries that have previously conducted MDA <sup>¥</sup>	All LF endemic countries <sup>¥</sup> , including all countries co-endemic with <i>L</i> . <i>loa</i>	All LF endemic countries <sup>4</sup> , including all countries co- endemic with <i>L. loa</i>	All LF endemic countries <sup>¥</sup> , including all countries co- endemic with <i>L. loa</i>
Rate of scale- up	Countries with previous MDA continue at same rate as historically	Countries with previous MDA continue at same historical rate, countries without previous progress begin at an 'average' rate of MDA scale-up (schedule II)	Schedule I: All countries add 20% of their at-risk populations to the MDA schedule annually	All countries treat 100% of their at-risk populations annually

\*Assuming country requires MDA


doi:10.1371/journal.pntd.0004147.t001

Kastner RJ, Tediosi F et al (2015) What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs. PLoS Negl Trop Dis 9(10)





### Impacts of LF elimination and eradication strategies



Kastner RJ, Tediosi F et al (2015) What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs. PLoS Negl Trop Dis 9(10)


### Maps of the final year of MDA per country







### Impacts of LF elimination and eradication strategies



Stone CM, Tediosi F et al. Modelling the health impact and cost-effectiveness of lymphatic filariasis eradication under varying levels of mass drug administration scale-up and geographic coverage. BMJ Global Health 2016;1





### Challenge 2: Shift in the disease burden towards non communicable diseases




Figure 2: Total DALYs, crude DALY rates, and age-standardised DALY rates from 1990 to 2013

Changes in global DALYs caused by communicable, maternal, neonatal, and nutritional disorders, non- communicable diseases, and injuries shown in terms of numbers of DALYs (A), DALY rates per 100 000 people (B), and age-standardised DALY rates per 100 000 people (C). The difference in trends between A and B is caused by population growth and the difference between B and C because of changes in the percentage distribution of the population by age. Shaded areas show 95% uncertainty intervals. DALY=disability-adjusted life-years.

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Aug 27.





## Challenge 2: Shift in the disease burden towards non communicable diseases

Example: Ghana burden of disease profile http://www.healthdata.org/ghana

<u>Ghana.pptx</u>





### Challenge 2: Shift in the disease burden towards non communicable diseases

- High social burden prolonged disability, less resources within families, reduced productivity
- More complex ways to deliver services e.g. coordination of care, integration of different levels of care, integration of health and social care
- The "medical-industrial complex" response to NCDs is expensive







### **NCDs WHO Global Health Observatory**

Policy: Existence of operational policy/strategy/action plan for cardiovascular diseases

http://gamapserver.who.int/gho/interactive\_charts/ncd/health\_systems/policy/atlas.html

Surveillance: Existence of an NCD surveillance and monitoring system in place to enable reporting against the nine global NCD targets

http://gamapserver.who.int/gho/interactive\_charts/ncd/health\_systems/surveillance/atlas.html





### Medical technologies is a driver of health expenditure

### Innovation in health care does not necessarily lead to increase in productivity as in other sectors

	Di Matteo <sup>15</sup>	Jones <sup>16</sup>	Pricewaterhouse	Smith	Peden and	Cutler <sup>9</sup>	Newhouse <sup>10</sup>
			Coopers <sup>7</sup>	et al <sup>19</sup>	Freeland <sup>17</sup>		
Life expectancy/aging	~ <b>9</b> %	aje	15%**	2%	<b>6%</b> – <b>7</b> %	2%	2%
Administrative costs	*	*	15%***	3%-10%	*	13%	*
Changes in financing	*	*	*	10%	4%5%	10%	10%
Personal income growth	<b>9%–20%</b>	*	*	11%-18%	14%-18%	5%	<23%
Health care prices	*	ale.	18%	11%-22%	*	<b>19</b> %	*
Technology	~65%	50%-75%	%25%	38%-62%	70%75%	<b>49</b> %	>65%

Table 3 Contributions of selected factors to growth in health care spending

Notes: \*Not estimated; \*\*included aging, but also "front page treatments" (ie, media coverage drives demand for expensive treatment), increased preventive and diagnostic activity, and consumers moving away from less expensive managed care products; \*\*\*\*included government mandates (including new mandated benefits) and federal and state regulatory requirements.


# Key to sustainability: «governing» use of medical technologies to improve population health





### **Physical resources for health in OECD countries**

Computed tomography (CT) scanners - / In hospitals / In ambulatory care providers Per 1,000,000 inhabitants, 2013









### **Physical resources for health in OECD countries**

Magnetic resonance imaging (MRI) units. Total / In hospitals / In ambulatory care providers, Per 1 000 000 inhabitants, 2013



Source: OECD Health care resources





# **Example: Differences in All-Cause Mortality and Length of Stay for Patients with Hip Fracture**

- Assessment of outcomes, use of services and costs for Hip fracture in 7 countries: Finland, Hungary, Italy, the Netherlands, Norway, Scotland, and Sweden
- Administrative datasets (registers) of use of services and medicines linked at indivdual level with mortality registers
- All-Cause Mortality and Length of Stay for Patients with Hip Fracture and association of them with selected country and regional level factors


Medin E, Tediosi F et al. 2015. European regional differences in all-cause mortality and length of stay for hip fracture patients. Health Economics 24 (Suppl. 1): 53-64.







### **Example: European Regional Differences in All-Cause Mortality and Length of Stay for Patients with Hip Fracture**



Medin E, Tediosi F et al. 2015. European regional differences in all-cause mortality and length of stay for hip fracture patients. Health Economics 24 (Suppl. 1): 53-64.

### b: National and regional variation in length of first hospital episode and during one-year (days), age-and sex-standardised

# variation in 30-day and one-year mortality rate (%), age and sex-standardised





# Swiss TPH

### **Example: European Regional Differences in All-Cause** Mortality and Length of Stay for Patients with Hip Fracture

- Remarkable variations in mortality and LoS, across countries and within countries
- Regression models showed variation in mortality & LoS weakly associated only with some country-level factors -e.g. clinical guidelines
- Variation probably due to broader health systems and societal factors - e.g. role of homecare, how societies deal with care of elderly people, etc.



### The "medical-industrial complex" response to NCDs

### Seeking sickness in contemporary health systems

- New diagnostic technologies continuously developed
- Culture that more diagnosis=more treatment=better health

"In the past, people sought health care because they were sick. Now the medical-industrial complex seeks patients. It encourages those with minor symptoms to be evaluated and urges those who feel well to get "checked" — just to make sure nothing is wrong" (H. Gilbert Welch, 2009)

# **Paradigm of Early Diagnosis**







### The "medical-industrial complex" response to NCDs

Opportunities to prevent symptomatic disease in some people, at the cost of maximizing the diagnosis in others who are not destined ever to develop symptoms or die



Occurs when people without symptoms are diagnosed with a disease that ultimately will not cause them to experience symptoms or early death (Welch G, et al, 2011.)





### Pathways to overdiagnosis

### **Expanding disease definitions** – new categories, lowering thresholds, changing diagnostic methods

Examples of changes disease definitions


	Disease pi		
Condition	Old definition	New definition	New cases
Change in threshold			
Diabetes			
Fasting sugar 140 to 126	11'697'000	13'378'000	1'681'00
Hypertesion			
Systolic BP 160 to 140	38'690'000	52'180'000	13'490'00
Diastolic BP 100 to 90	38 090 000	52 180 000	13 490 00
Hyperlipidemia			
Total cholesterol 240 to 200	49'480'000	92'127'000	42'647'00
Osteoporosis			
T score -2.5 to -2.0	8'010'000	14'791'000	6'781'00

H. Gilbert Welch et al (2012). Overdiagnosed: Making People Sick in the Pursuit of Health











### Balancing benefits and harms of overdiagnosis

**Example: Chance benefit of cholesterol medicines for near** normal cholesterol

If 100 patients are diagnosed with near normal cholesterol and treated for a lifetime, how many will be:

Winners: Tratment saved them from first major heart eve

**Treated for Naught:** Had first major heart events despite treatment

**Losers:** Overdiagnosed – treatment couldn't help them because they were never going to have heart events

H. Gilbert Welch et al (2012). Overdiagnosed: Making People Sick in the Pursuit of Health





ent	8
	14
	78

### **Example of overdiagnosis – Breast cancer**

Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Jun 4;

> For every 2000 women (50 years old) invited for mammography screening throughout 10 years



### Harms:

- 10 healthy women will be treated unnecessarily
- More than 200 women will experience psychological distress for years because of false positive findings











### Pathways to overdiagnosis

**Overdiagnosis made incidentally—"incidentalomas"** 

- In 1000 people with no symptoms who elected to undergo totalbody CT screening:
  - 86% had at least one abnormality detected
  - The average individual had 2.8 abnormalities

(Frtado CT et al. Radiology 237 (2005):385-94)








58

# Challenge 3: Burden of medical expenditure on households and societies

- **Micro- households level:** Impoverishing effects of medical 1. expenditures:
  - Every year 100 million are pushed into poverty and 150 million people suffer financial catastrophe because of out-of-pocket expenditure on health services -Xu K, Evans DB, et al (2007)
  - About a quarter of households in low income and middle-income countries borrow money or sell items to pay for health care - Kruk ME et al (2009)
- **2.** Macro level: Global Health Expenditure 10% of global GDP huge differences across countries unrelated to burden of disease








Percentage distribution of population and total health expenditures by WB Income groups, 2014



Populations as % of world Health expenditure in USD as % of world



Stacked bar chart by financing agents, 2014






Social health insurance Private prepaid plans Out-of-pocket Territorial government

Other Private

### General government expenditure on health as a percentage of total government expenditure, 2014 \*



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: Global Health Observatory, WHO Map Production: Information Evidence and Research (IER) World Health Organization




© WHO 2017. All rights reserved.







### **Out-of-pocket expenditure on health** as a percentage of total expenditure on health (%), 2014 \*



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for World Health Organization which there may not yet be full agreement.

Data Source: Global Health Observatory, WHO Map Production: Information Evidence and Research (IER)



© WHO 2017. All rights reserved.












### **Out-of-pocket expenditure on health** as a percentage of private expenditure on health (%), 2014 \*



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for World Health Organization which there may not yet be full agreement.

Map Production: Information Evidence and Research (IER)
















© WHO 2017. All rights reserved.

Figure 3.5. No health spending by expenditure quintile (Q), median values of 37 countries (headcount ratio, percentage)







### Challenge 3: Burden of medical expenditure on households and societies

US Institute of Medicine (2010):

- "The growth rate of health care expenditures is unsustainable, with waste that diverts major resources from necessary care and other priorities
  - ...". Sources of inefficiencies include:
  - Scientific uncertainty about effectiveness and cost, especially of newer test and treatments
  - Cultural predisposition to believe that more care is better
- Innovations in health sector do not necessarily lead to increase in productivity as in other sectors - medical technologies major driver of health expenditure growth





### **Sources of data**

National Health Accounts http://apps.who.int/nha/database

Global Health Observatory http://who.int/gho/database/en/

WHO Global Health Expenditure Database: http://apps.who.int/nha/database/ViewData/Indicators/en



